一例转移性直肠癌患者多学科协作多线治疗体会

病例讨论

苑仁冰¹, 庄永志¹^,^†(

)

全文 ( ) 下载PDF ( ) 导出引用

图4 结肠癌肝转移患者于2010年12月行肝脏增强CT检查图像

[1]	Van Cutsem E，Nordlinger B，Adam R，et al.Towards a pan-European consensus on the treatment of patients with colorectal liver metastases.Eur J Cancer，2006,42:2212-2221.
[2]	Pawlik TM，Scoggins CR，Zorzi D，et al.Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases.Ann Surg，2005,241:715-722.
[3]	Andreou A，Brouquet A，Abdalla EK，et al.Repeat hepatectomy for recurrent colorectal liver metastases is associated with a high survival rate.HPB(Oxford)，2011,13:774-782.
[4]	Chibaudel B，Maindrault-Goebel F，Lldeo G，et al.Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 study.J Clin Oncol，2009,27(34):5727-5733.
[5]	Tabernero J，Aranda E，Gomez A，et al.Phase Ⅲ study of first-line XELOX plus bevacizumab(BEV)for 6 cycles followed by XELOX plus BEV or single agent(s/a)BEV as maintenance therapy in patients with metastatic colorectal cancer(mCRC)．The MACRO trial.Chicago，Illinois：McCormick Palace，ASCO 2010 abstract 3501.

No related articles found!

阅读次数

全文

摘要